Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 27, 2024
[ 05:03 PM ] - United States, Thomas Matters
[ 05:03 PM ] - United States, Thomas Matters
[ 05:03 PM ] - United States, Thomas Matters
[ 05:02 PM ] - United States, Thomas Matters
[ 05:02 PM ] - United States, Thomas Matters
[ 05:02 PM ] - United States, Thomas Matters
[ 05:02 PM ] - United States, Thomas Matters
[ 05:02 PM ] - United States, Thomas Matters
[ 05:02 PM ] - United States, Thomas Matters
[ 05:02 PM ] - United States, Thomas Matters
[ 05:01 PM ] - United States, Thomas Matters
[ 05:01 PM ] - United States, Thomas Matters
[ 05:01 PM ] - United States, Thomas Matters
[ 05:01 PM ] - United States, Thomas Matters
[ 05:00 PM ] - United States, Thomas Matters
[ 04:41 PM ] - United States, Thomas Matters
[ 04:41 PM ] - United States, Thomas Matters
[ 04:00 PM ] - United States, Thomas Matters
[ 03:40 PM ] - United States, Thomas Matters
[ 02:40 PM ] - United States, Thomas Matters
[ 02:20 PM ] - United States, Thomas Matters
[ 01:41 PM ] - United States, Thomas Matters
[ 01:00 PM ] - United States, Thomas Matters
[ 12:00 PM ] - United States, Thomas Matters
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
- For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank,
The article from MSN Money discusses why Catalyst Pharmaceutical (CPRX) is considered a strong momentum stock. It highlights that CPRX has shown significant positive momentum in its stock price, with a 1.86% increase last week, outperforming the Zacks Medical - Drugs industry which saw a 0.35% rise. Over longer periods, CPRX has also performed well, with a 13.86% increase in the last quarter and a 110.75% rise over the past year, compared to the S&P 500's 10.16% and 27.47% respectively. The stock's momentum is further supported by positive earnings estimate revisions; over the past two months, the consensus estimate for the full year has increased from $1.11 to $1.46. This upward trend in earnings estimates, combined with strong stock price performance, has led to CPRX receiving a Momentum Style Score of A and a Zacks Rank of #2 (Buy), making it an attractive option for investors looking for momentum stocks.
Read the Full MSN Article at [ https://www.msn.com/en-us/money/topstocks/here-s-why-catalyst-pharmaceutical-cprx-is-a-strong-momentum-stock/ar-AA1uRvLS ]
Read the Full MSN Article at [ https://www.msn.com/en-us/money/topstocks/here-s-why-catalyst-pharmaceutical-cprx-is-a-strong-momentum-stock/ar-AA1uRvLS ]
